Alnylam unveils a novel pricing strategy for its second RNAi launch, which was greenlit by the US regulator with notable speed.
Innovate combines with RDD, but the success of the takeover relies in large part on a project for coeliac disease.
Genfit's quiet delay means it will be five years since a Nash failure before investors find out whether pressing on into phase III was worth it.
Reneuron is set to release further data with its hRPC stem cell therapy in retinitis pigmentosa, while Provention Bio aims to target Crohn’s early with PRV-6527.
With the buyout of Sitari Pharmaceuticals, Glaxosmithkline becomes only the second major drug maker to have an interest in coeliac disease.
The Danish group tops the list, while Ardelyx could get its first nod for tenapanor, and Xeris gets a second shot with its hypoglycaemia rescue pen.
The company’s Enigma study in an orphan digestive tract disease points a way to approval, notwithstanding the company’s statistical analysis method.
Newly-listed NGM Biopharmaceuticals needs its Nash project to impress in phase II, while Enanta must show that it also has a foot in the door in the liver disease.
Paying $40m up front for a preclinical asset is a bold move, even for the red-hot Nash space, though Boehringer has shelled out here before.